AI assistant
Sending…
ATOSSA THERAPEUTICS, INC. — Director's Dealing 2023
May 6, 2023
34113_dirs_2023-05-05_76e06563-99f7-4a74-aee7-354d44fcf282.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ATOSSA THERAPEUTICS, INC. (ATOS)
CIK: 0001488039
Period of Report: 2023-05-04
Reporting Person: Remmel H. Lawrence (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-05-04 | Stock Option (right to buy) | $0.662 | A | 125000 | Acquired | 2033-05-04 | Common Stock (125000) | Direct |
Footnotes
F1: The options shall vest on a quarterly basis over the next 12 months. The options were issued at approximately 9:50 a.m. (ET) on May 4, 2023, with an exercise price of $0.662, representing the most recently reported closing stock price on May 3, 2023.
More from ATOSSA THERAPEUTICS, INC.
Regulatory Filings
2026
May 8
Interim / Quarterly Report
2026
May 8
Declaration of Voting Results & Voting Rights Announcements
2026
May 8
Regulatory Filings
2026
Apr 16
Director's Dealing
2026
Mar 31
Annual Report
2026
Mar 25
Proxy Solicitation & Information Statement
2026
Mar 20
Capital/Financing Update
2026
Feb 20
Delisting Announcement
2026
Feb 17
Regulatory Filings
2026
Feb 11